Literature DB >> 9849308

Lymphadenopathy in a patient with systemic onset juvenile chronic arthritis.

R Munro1, D R Porter, R D Sturrock.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9849308      PMCID: PMC1752745          DOI: 10.1136/ard.57.9.513

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  6 in total

1.  Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria.

Authors:  Tim Niehues; Gerd Horneff; Hartmut Michels; Michaela Sailer Höck; Lothar Schuchmann
Journal:  Rheumatol Int       Date:  2005-02-02       Impact factor: 2.631

Review 2.  Recommendations for the use of methotrexate in juvenile idiopathic arthritis.

Authors:  Tim Niehues; Petra Lankisch
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 3.  [Methotrexate in the therapy of juvenile idiopathic arthritis].

Authors:  D Holzinger; M Frosch; D Föll
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

Review 4.  Cervical lymph node diseases in children.

Authors:  Stephan Lang; Benjamin Kansy
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2014-12-01

Review 5.  Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition.

Authors:  Sriharsha Grevich; Susan Shenoi
Journal:  Adolesc Health Med Ther       Date:  2017-11-09

Review 6.  Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting.

Authors:  Giovanna Ferrara; Greta Mastrangelo; Patrizia Barone; Francesco La Torre; Silvana Martino; Giovanni Pappagallo; Angelo Ravelli; Andrea Taddio; Francesco Zulian; Rolando Cimaz
Journal:  Pediatr Rheumatol Online J       Date:  2018-07-11       Impact factor: 3.054

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.